Vaxart, Inc.

VXRT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2009
Revenue $10.5M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $16.5M
SG&A Expense $10.0M
Operating Income $-18.0M
Operating Margin -171.4%
Interest Expense $1.1M
Pretax Income $-18.7M
Income Tax Expense
Net Income $-18.7M
Net Margin -178.5%
EPS (Basic) $-0.37
EPS (Diluted) $-0.37
Shares Outstanding (Basic) 50.6M
Shares Outstanding (Diluted) 50.6M
Dividends Per Share
← Newer Page 3 of 3 Older →